A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma. Bond DA, Huang Y, Christian BA, Jaglowski S, et al. Leuk Lymphoma 2022 Feb 6:1-4. doi: 10.1080/10428194.2022.2034154.

Read + Share

Amedeo Smart

Independent Medical Education

Bond DA, Huang Y, Christian BA, Jaglowski S, et al. A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma. Leuk Lymphoma 2022 Feb 6:1-4. doi: 10.1080/10428194.2022.2034154.
PMID: 35129029